Form 4: Elanco Animal Health CEO Jeffrey Simmons Reports Acquisition of Deferred Stock Units

Elanco Animal Health's CEO, Jeffrey N. Simmons, acquired deferred stock units convertible to common stock, as reported in a recent SEC filing.

Summary

• On April 5, 2024, Jeffrey N. Simmons, the CEO and a director of Elanco Animal Health Inc., acquired 177.9717 deferred stock units.
• These units represent the right to receive one share of Elanco's common stock or the cash equivalent.
• The price per unit was $15.56.
• Following the transaction, Simmons directly owns 1,224.4426 shares.
• The deferred stock units will settle in cash or shares of Elanco common stock following termination of employment or during a specified future year, according to the Executive Deferral and Stock Match Plan.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a routine executive compensation transaction, indicating confidence in the company's future performance.

Future Outlook

The deferred stock units will settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.

Industry Context

This filing reflects standard executive compensation practices within publicly traded companies, where stock-based compensation is used to align executive interests with shareholder value. The acquisition of deferred stock units is a common method of incentivizing long-term performance.

Stakeholder Impact

• The acquisition of deferred stock units by the CEO aligns his interests with those of the shareholders, potentially driving long-term value creation.

Key Dates